Francesco Trevisani

Dr. Francesco Trevisani is a nephrologist in the Urology Department of the Hospital of the IRCCS Ospedale San Raffaele, headed by Professor Francesco Montorsi. He is also involved in medical activities at the Casa di Cura La Madonnina.

Dr. Trevisani graduated from the Faculty of Medicine and Surgery of the Vita Salute San Raffaele University of Milan in 2009 with a thesis on the genetics of nephropathies. In 2015, he majored with honors in nephrology at the same university under the guidance of Professor Paolo Manunta, having defended his thesis "Molecular and Clinical Biomarkers of Chronic Kidney Disease and Hypertension following Radical Nephrectomy for Renal Carcinoma, an experimental translated dissertation that received an award from the Italian Society of Nephrologists and completed during the last year of specialization at the Center Of Molecular Pathology, The Institute of Cancer Research , The Royal Marsden, London, under the supervision of Professor Nicola Valeri. In 2019, he received an international doctorate with honors in molecular medicine from the Vita-Salute San Raffaele University as part of the translational research project "Kidney cancer and renal surgery: new molecular and histological predictors of cancer aggressiveness and glomerular filtration rate decline" under the guidance of Prof. Francesco Montorsi. Subsequently, the dissertation contributed to the creation of an international patent application filed in January 2020 at the PCT.

From a clinical point of view, Dr. Trevisani works as a consultant nephrologist in the Department of Urology under the supervision of Professor Francesco Montorsi, dealing mainly with onconephrology and uronephrology.

As for scientific activity, the doctor is engaged in clinical and translational research at the Urological Research Institute (URI) under the supervision of Professor Andrea Salonia. Together with Dr. Arianna Bettiga, she is responsible for the international translational research project RE.ME.DIET., aimed at preventing kidney diseases through epigenetic modifications stimulated by the Mediterranean diet.

Dr. Trevisani has also been a member of the European Society of Nephrology (ERA-EDTA) since 2014, and since 2017 he has become a board member of the International Nephrology Group DIABETES, a working group created by ERA-EDTA to study the relationship between kidney disease, diabetes and obesity. He annually participates in international congresses in the field of nephrology and urology, presenting the results of translational research conducted within the framework of the Urological Research Institute.

Finally, Dr. Trevisani is the founder and CEO of the biomedical startup "Biorek", aimed at creating new diagnostic kits for the diagnosis and prediction of kidney cancer; in 2017, he was among the winners of the first issue of the acceleration project "Open Accelerator Z-Cube", created by the pharmaceutical group Zambon for "BIOREK, Biomarkers of Renal Cancer".

The Doctor's publications are available here